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Abstract
Background: Image-guided surgery may improve surgical outcome for colorectal cancer patients. Here, we evaluated
the feasibility of a pretargeting strategy for multimodal imaging in colorectal cancer using an anti-carcinoembryonic
antigen (CEA) x anti-histamine-succinyl-glycine (HSG) bispecific antibody (TF2) in conjunction with the dual-labeled
diHSG peptide (RDC018), using both a fluorophore for near-infrared fluorescence imaging and a chelator for
radiolabeling.
Methods: Nude mice with subcutaneous (s.c) CEA-expressing LS174T human colonic tumors and CEA-negative control
tumors were injected with TF2. After 16 h, different doses of 111In-labeled IMP-288 (non-fluorescent) or its fluorescent
derivative RDC018 were administered to compare biodistributions. MicroSPECT/CT and near-infrared fluorescence
imaging were performed 2 and 24 h after injection. Next, the biodistribution of the dual-labeled humanized anti-CEA IgG
antibody [111In]In-DTPA-hMN-14-IRDye800CW (direct targeting) was compared with the biodistribution of 111In-RDC018 in
mice with TF2-pretargeted tumors, using fluorescence imaging and gamma counting. Lastly, mice with intraperitoneal
LS174T tumors underwent near-infrared fluorescence image-guided resection combined with pre- and post-resection
microSPECT/CT imaging.
Results: 111In-RDC018 showed specific tumor targeting in pretargeted CEA-positive tumors (21.9 ± 4.5 and 10.0 ± 4.7%
injected activity per gram (mean ± SD %IA/g), at 2 and 24 hours post-injection (p.i.), respectively) and a biodistribution
similar to 111In-IMP288. Both fluorescence and microSPECT/CT images confirmed preferential tumor accumulation. At post
mortem dissection, intraperitoneal tumors were successfully identified and removed using pretargeting with TF2 and
111In-RDC018.
Conclusion: A pretargeted approach for multimodal image-guided resection of colorectal cancer in a preclinical
xenograft model is feasible, enables preoperative SPECT/CT, and might facilitate intraoperative fluorescence imaging.
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Introduction
Colorectal cancer is the third most common cause of can-
cer deaths in the Western world [1]. In different stages of
disease, surgery is a crucial part of the (curative) treatment
of patients and complete resection of malignant tissue re-
mains one of the main prognostic factors [2]. Surgical out-
come may be improved by better pre- and intraoperative
imaging tools to aid the surgeon in patient selection,
tumor detection, and radical resection. Intraoperative
fluorescence imaging has shown potential to increase spe-
cificity and sensitivity of resections [3]. A combined ap-
proach to improve both pre- and intraoperative tumor
detection using tumor-targeted multimodal imaging may
be advantageous to achieve the best surgical outcome.
Overexpression of carcinoembryonic antigen (CEA) is
present in 90–95% colorectal cancers [4, 5]. This bio-
marker may be targeted by the high-affinity monoclonal
antibody hMN-14. hMN-14 is a humanized IgG directed
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against the carcinoembryonic antigen-related cell adhe-
sion molecule 5 [6]. In a previous study, hMN-14 labeled
with Indium-111 (111In) and conjugated to IRDye800CW
([111In]In-DTPA-hMN-14-IRDye800CW) was shown to
specifically accumulate in CEA-expressing tumor xeno-
grafts and enabled radio- and fluorescence-guided sur-
gery of colorectal tumor nodules [7]. However, due to
the slow blood clearance of antibodies, high tumor-to-
background signals can only be achieved at several days
after injection.
An alternative approach to deliver radioactive, fluor-
escent, or other agents to tumors for imaging and
therapy is via a pretargeting strategy [8]. In this mul-
tistep approach, first a bispecific antibody (bsAb) is
administered that specifically targets the tumor. Sub-
sequently, a hapten, carrying a diagnostic or thera-
peutic load, is administered that binds to the bsAb.
This hapten is a relatively small molecule with rapid
renal clearance. Both high specificity and high tumor-
to-background ratios may be achieved using this
strategy, as it combines the specific targeting proper-
ties of antibodies with the favorable pharmacokinetics
and clearance of small molecules [9–14].
The current study investigates the use of a tumor-
specific multimodal pretargeting strategy. For this
purpose, we apply the trivalent bispecific anti-CEA x
anti-histamine-succinyl-glycine (HSG) antibody TF2 in
combination with the multimodal di-HSG hapten-pep-
tide RDC018, an IMP-288 derivative (Additional file
1: Figure S1). RDC018 contains both a fluorophore
and a chelator for 111In labeling, thus enabling both
radionuclide and fluorescence imaging, whereas IMP-
288 only harbors a chelator and no fluorophore. Here,
we evaluate the feasibility of this multimodal pretar-
geting approach in a colorectal cancer model of peri-
toneal metastasis.
Methods
Pretargeting molecules TF2 and RDC018
The bsAb TF2 contains two CEACAM5 and one HSG-
binding sites [13] and was produced using the Dock-
and-Lock method as described previously [15]. A sche-
matic representation of the pretargeting agents is pro-
vided by Schoffelen et al. [13]. RDC018 is a peptide-
hapten derived from IMP-288, a 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated
D-Tyr-D-Lys-D-Glu-D-Lys tetrapeptide, in which both
lysine residues are substituted with a HSG moiety via
their ε-amino group (Additional file 1: Figure S1) [16].
In addition to the DOTA chelate for radiolabeling,
RDC018 is C-terminally conjugated with the fluores-
cent DyLightTM 800 NHS ester. TF2 [15] and RDC018
were kind gifts from Immunomedics Inc.
Radiolabeling
All labeling procedures were performed under metal-free
conditions. Briefly, [111In]InCl3 (Mallinckrodt Medical
BV/Curium, Petten, the Netherlands) was added to
IMP-288 or RDC018 in two volumes of 0.1M 2-(N-mor-
pholino)ethanesulfonic acid (MES), pH 5.5. After 20 min
of incubation at 95 °C, 50 mM ethylenediaminetetraace-
tic acid (EDTA) was added to the labeling reaction to a
final concentration of 1 mM EDTA to chelate unincor-
porated 111In. Lastly, Tween80 (Sigma-Aldrich, Saint
Louis, MO, USA) was added to the labeling product in a
final concentration of 0.01%. The labeling efficiency was
determined by instant thin-layer chromatography on
Varian silica gel strips (ITLC-SG; Agilent Technologies,
Amstelveen, the Netherlands) using 0.1 mM ammonium
acetate (NH4Ac) buffer with 0.1M EDTA (pH 5.5) as the
mobile phase. If labeling efficiency was below 95%, la-
beled products were purified using solid-phase extrac-
tion on an HLB cartridge (Waters Chromatography B.V.,
Etten-Leur, the Netherlands) with 100% EtOH as mobile
phase. Final radiochemical purity was > 95% for all
compounds.
The antibody hMN-14 was conjugated to
IRDye800CW (fluorophore:antibody substitution ratio
1.4) and diethylenetriaminepentaacetic acid (DTPA)
which was labeled with [111In]InCl3 at a specific activity
of 0.78MBq μg−1, as previously described [7].
Cell culture
CEA-expressing human colon adenocarcinoma cells
LS174T and CEA-negative human renal cell carcinoma
cells SK-RC-52 were obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA). Cells
were tested for mycoplasma negativity. Cells were cul-
tured in sterile conditions using RPMI-1640 medium
supplemented with 10% heat-inactivated fetal calf serum
and 2mM L-glutamine, without antibiotic additive. Cells
were cultured in T150 tissue culture flasks in a humidi-
fied incubator with an atmosphere of 95% air and 5%
carbon dioxide at 37 °C. All cells were harvested with
trypsin/EDTA.
Xenograft mouse models
All animal experiments were approved by the Institutional
Animal Welfare Committee of the Radboud University
Medical Center and were conducted in accordance to the
guidelines of the Revised Dutch Act on Animal Experi-
mentation (2014).
Female BALB/cAnNRj-Foxn1nu/nu nude mice (7–9
weeks-old, 18–22-g body weight; Janvier), housed in indi-
vidually ventilated cages (5 mice per cage) under non-sterile
standard conditions with free access to standard animal
chow and water, were adapted to laboratory conditions for
1 week before experimental use. For the biodistribution and
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microSPECT/CT experiments, mice were subcutaneously
inoculated with 2 × 106 LS174T cells (left flank) and 2 × 106
SK-RC-52 cells (right flank) both suspended in 200 μL
RPMI-1640 medium. For the image-guided resection ex-
periment, intraperitoneal tumor growth was induced by an
intraperitoneal injection of 3 × 105 LS174T cells suspended
in 200 μL RPMI-1640 medium. Tail vein injections were
performed for intravenous administration of antibodies and
peptides.
Biodistribution studies
Biodistribution of 111In-IMP-288 versus 111In-RDC018
In the first experiment, the biodistributions of 111In-
IMP-288 and 111In-RDC018 were compared. Three dif-
ferent dose levels (0, 0.8, and 8 nmol) of TF2 or controls
were tested with a 1:20 TF2:HSG-peptide ratio of each
HSG-peptide in two subsets of 30 mice (5 mice per
group). Mice at the zero dose level received the same
amount of HSG-peptide (0.4 nmol) as mice at the high-
est dose level. Seventeen days after tumor inoculation,
200 μL TF2 in PBS-0.5% BSA or PBS-0.5% BSA was
injected intravenously. Sixteen hours following TF2 ad-
ministration, the radiolabeled HSG peptide (111In-IMP-
288, 9.5MBq μg−1 or 111In-RDC018, 5.8MBq μg−1) was
injected. Mice were euthanized by CO2/O2 asphyxiation,
and the biodistribution of 111In-IMP-288 and 111In-
RDC018 was determined 2 or 24 h after peptide injec-
tion. For this purpose, tissues of interest (tumor, muscle,
lung, spleen, kidney, liver, pancreas, stomach, and duo-
denum) were dissected and weighed after which activity
was measured in a shielded 3-in.-well-type γ-counter
(Perkin-Elmer, Boston, MA, USA). Blood samples were
obtained by heart puncture. For calculation of the up-
take of activity in each tissue as a fraction of the injected
activity, three aliquots of the injection dose were
counted in the γ-counter simultaneously.
Biodistribution of 111In-RDC018 versus dual-labeled hMN-14
In the second experiment, the biodistribution profile of
111In-RDC018 in the pretargeted approach (TF2-RDC018)
was compared to the dual-labeled humanized monoclonal
antibody hMN-14 (reference compound) using the IVIS
Lumina fluorescence camera (Xenogen VivoVision IVIS
Lumina II, Caliper Life Sciences, Waltham, MA, USA)
and MicroSPECT/CT (U-SPECT II; MILabs, Utrecht, the
Netherlands). TF2 (1.4 nmol) and [111In]In-DTPA-hMN-
14-IRdye800CW (32.2 μg, 0.78MBq μg−1) were injected
intravenously 17 days following subcutaneous tumor cell
inoculation in two groups of 5 mice. Radiolabeled
RDC018 (126MBq μg−1, 0.18 μg per mouse, 22MBq per
mouse) was administered 16 h following TF2 injection.
Mice which received TF2 and 111In-RDC018 were imaged
at two time points (2 and 24 h post administration of the
radiolabeled peptide). The reference group (n = 5) was im-
aged 24 and 48 h after dual-labeled hMN-14 injection.
MicroSPECT/CT and near-infrared fluorescence (NIRF)
imaging
Mice with one CEA-positive and one CEA-negative
tumor were scanned on a small-animal microSPECT/CT
scanner with a 1.0-mm diameter pinhole collimator tube
(acquisition time, 2 × 15min) in prone position, followed
by a CT scan (spatial resolution, 160 μm; 65 kV; 612 μA)
for anatomical reference.
MicroSPECT/CT scans were reconstructed with
MILabs reconstruction software, which uses an ordered-
subset expectation maximalization algorithm.
NIRF images were acquired on the IVIS fluorescence
imaging system (acquisition time, 5min; binning, medium;
Fstop, 2; excitation, 745 nm; excitation autofluorescence,
675 nm; emission, ICG; lamp level, high; FOV, D).
Image-guided (post mortem) resection
After the biodistribution experiments, an image-guided
resection experiment was performed. Intraperitoneal tu-
mors were induced in 3 groups of mice and after 3
weeks the targeting agents were administered. In the
first group, 6 nmol of TF2 was administered to 5
mice and 16 h following TF2 injection, 0.3 nmol of
radiolabeled RDC018 was administered. Two hours
following 111In-RDC018 injection, mice were imaged
with microSPECT/CT and NIRF imaging. Hereafter,
image-guided resection using the IVIS fluorescence
imaging system was performed. To confirm complete
resection, additional optical imaging and SPECT/CT
images were acquired. Next, animals were dissected
to determine the biodistribution of the radiolabeled
peptide as described above.
The two remaining groups of mice served as controls.
In two mice, peritoneal tumors grew faster than ex-
pected and reached a humane endpoint before the start
of the experiment. These mice were therefore eutha-
nized prior to injection of the control compounds. As a
result, each control group consisted of 4 mice. In the
first group, (positive control) dual-labeled hMN-14 [7]
was administered to 4 mice with intraperitoneal LS174T
tumors. Resection and analysis were performed 3 days
after dual-labeled hMN-14 injection. As negative con-
trol, we used 4 mice with tumors pretargeted with the
trivalent anti-CD20 bsAb TF4 [17] in combination with
111In-RDC018 with the same dosing and timing as the
TF2 group.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software (version 5.03; GraphPad Software). Student’s t test
was performed on the biodistribution studies IMP288
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versus RDC018 (tumor, blood, and kidney), corrected for
multiple testing (Bonferroni). A p value < 0.05 was used to
reject the null hypothesis. Data are presented as mean and
standard deviation.
Results
Biodistribution
To gain more insight into differences in the in vivo be-
havior between 111In-RDC018 and 111In-IMP-288, mice
with subcutaneous tumors received different dose levels
of TF2 and hapten-peptide. The biodistribution of 111In-
RDC018 revealed high and target-specific uptake in
CEA-expressing TF2-pretargeted tumors after 2 and 24
h (22.0 ± 4.5 %IA/g and 10.0 ± 4.7 %IA/g, respectively). In
contrast, uptake of 111In-RDC018 remained low in CEA-
negative tumors (6.0 ± 1.8 %IA/g and 0.9 ± 0.4 %IA/g, re-
spectively) as well as in other healthy tissues. Compared
to the reference compound 111In-IMP-288, 111In-
RDC018 showed similar tumor-specific uptake in CEA-
positive TF2-pretargeted tumors (Fig. 1, 8 nmol; TF2,
Additional file 2: Figure S2, 0 nmol and 0.8 nmol TF2).
However, in CEA-negative tumors, uptake of 111In-
RDC018 was significantly higher than the uptake of
111In-DOTA-IMP-288 (0.13 ± 0 %IA/g and 0.07 ± 0 %IA/
g p < 0.001). The same observation was made for tracer
accumulation in the kidney and blood, which was signifi-
cantly higher for 111In-RDC018 compared to 111In-IMP-
288 after 2 and 24 h (both p < 0.001). For 0.8 nmol TF2,
tumor uptake of pretargeted LS174T tumors was signifi-
cantly higher compared to the negative control tumors
for both time points. In more detail, for 0.8 nmol TF2
and 2 h after peptide injection, the uptake in CEA-posi-
tive LS174T tumors was 22.0 ± 4.5 %IA/g and 6.0 ±
1.8 %IA/g in CEA-negative SK-RC-52 tumors (p <
0.001). This difference remained 24 h after peptide injec-
tion (10.0 ± 4.7 %IA/g and 0.9 ± 0.4 %IA/g (p < 0.001), re-
spectively). We did not observe a statistically significant
difference in uptake between 111In-RDC018 and 111In-
IMP-288 for both time points. For 8.0 nmol TF2, we ob-
served similar results (Fig. 1). Two hours after peptide
injection, uptake was 9.9 ± 0.4 %IA/g for LS174T and
3.8 ± 0.6 %IA/g for SK-RC-52 cells (p < 0.001). This dif-
ference remained 24 h after peptide injection (10.2 ±
1.9 %IA/g and1.6 ± 0.3 %IA/g (p < 0.001), respectively).
Two hours after peptide injection, 111In-RDC018 uptake
in LS174T tumors was higher than 111In-IMP-288: 9.9 ±
0.4 %IA/g and 5.3 ± 1.8 %IA/g (p = 0.0135). After 24 h,
however, the uptake of 111In-RDC018 and 111In-IMP-
288 was not statistically significantly different (10.2 ± 1.9
and 6.6 ± 2.9 (p = 0.2713).
To compare the in vivo behavior of 111In-RDC018 in
TF2-pretargeted tumors to dual-labeled hMN-14 (direct
targeting), the biodistribution patterns of both approaches
were characterized. Both tracers were shown to specifically
target the CEA-expressing tumors which was confirmed by
microSPECT/CT and NIRF imaging (Fig. 2). Also, the ex-
cretion routes of 111In-RDC018 (via the kidneys) and
111In-hMN-14-IRDye800CW (via the liver) was clearly
illustrated (Fig. 2).
Fluorescence imaging
In addition to the quantitative biodistribution studies
based on the radiobsignal, we assessed tumor accumula-
tion and distribution of the tracer by NIRF imaging. The
imaging results show a similar distribution pattern com-
pared to the quantitative biodistributions (Fig. 3), dem-
onstrating that our pretargeted approach can be used for
NIRF imaging of CEA-positive tumors, which is essential
for reliable image-guided surgery.
Image-guided (post mortem) resection
Finally, we assessed the feasibility for pretargeted image-
guided surgery in a more clinically relevant setting in
mice with intraperitoneal LS174T tumors undergoing re-
section. RDC018 was labeled at a specific activity of 20.1
MBq μg−1. The microSPECT/CT images clearly identi-
fied intraperitoneal tumors (Fig. 4). Subsequently, NIRF
imaging was able to identify these tumors and serve as
guidance during (post mortem) resection. Finally, post-
resection microSPECT/CT and NIRF imaging confirmed
complete resection of tumor tissue (Fig. 4).
Discussion
In the present study, we show that pretargeted multi-
modal image-guided resection is feasible in a model for
peritoneal metastasis. 111In-RDC018 accumulation in the
tumor is specific and RDC018 clears via the kidneys in
Fig. 1 Biodistribution profiles of 111In-RDC018 and 111In-IMP-288 at
2 h and 24 h p.i. after pretargeting with 8 nmol TF2 in BALB/c nude
mice, showing specific tumor uptake in the s.c. CEA-expressing
LS174T tumor and pronounced renal uptake
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TF2-pretargeted intraperitoneally xenografted tumors.
These characteristics enabled “preoperative” micro-
SPECT and “intraoperative” NIRF imaging for successful
image-guided post mortem resection and confirmation
of complete tumor resection by postoperative SPECT.
For the pretargeting strategy to work, the bispecific anti-
body should not show fast internalization. TF2 internalizes
only minimally [18]. Furthermore, Schmidt et al. showed
that CEA is a slowly and minimally internalizing antigen
[19]. RDC018 is an IMP-288 derived hapten-peptide con-
jugated with a fluorescent moiety. To evaluate the effect
of the fluorophore of RDC018 on the in vivo behavior of
the molecule, the biodistribution was compared to that of
IMP-288. Our results illustrate that 111In-RDC018 and
111In-IMP-288 have, apart from uptake in the CEA-
negative tumor and kidneys, similar distribution pat-
terns after TF2 pretargeting (Fig. 1). However, there
is more nonspecific uptake of 111In-RDC018 across all
included organs. These findings suggest that the
fluorophore does not relevantly compromise the par-
ental molecule’s binding properties and in vivo behav-
ior. We did, however, find a higher uptake of 111In-
RDC018 in the CEA-negative SK-RC-52 tumors (Fig.
1), which indicates more nonspecific uptake of the
tracer, possibly due to different molecular characteris-
tics of the dye (e.g., lipophilicity and charge) and/or
the enhanced permeability and retention effect due to
the longer blood retention time [20]. An earlier study
indicated that high dye:antibody conjugation ratios (> 2)
can significantly change biodistributions of antibody-dye
conjugates [21]. Therefore, the smaller molecule 111In-
RDC018 contains a single fluorescent moiety and hMN-
14 was conjugated at a final dye:antibody ratio of 1.4. Fur-
ther evaluation of chemical differences was beyond the
scope of this study. The uptake of 111In-RDC018 in CEA-
positive tumors, however, was large enough to provide
sufficient tumor-specific uptake for imaging purposes
(Figs. 2, 3, and 4). Earlier studies already showed that a
non-CEA-specific pretargeting IgG combined with a radi-
olabeled hapten resulted in very low tumor uptake [18].
Kidney uptake was higher for 111In-RDC018 than for
111In-IMP-288, indicating enhanced tubular reabsorption
Fig. 2 Near-infrared fluorescence (left) and microSPECT/CT (right) images of mice bearing s.c. CEA-expressing tumors (left flank), acquired using
the TF2-111In-RDC018 pretargeting strategy (a) or the dual-labeled hMN-14 direct targeting strategy (b). Both series were acquired 24 h post
injection. Note the uptake in the tumor, liver, and kidneys depending on tracer type
Fig. 3 Near-infrared fluorescence image 24 h p.i. of 111In-RDC018 in
a mouse bearing a s.c. CEA-expressing LS174T tumor (left flank) and
a s.c. CEA-negative SK-RC-52 tumor (right flank), confirming the
specific tumor targeting in the CEA-expressing tumor and renal
clearance (black arrows) of 111In-RDC018
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of the dual-labeled peptide in the kidneys, most probably
caused by charge of the fluorescent moiety.
Sharkey et al. and Lütje et al. demonstrated a pretar-
geted approach for radioimmunotherapy and image-
guided surgery in a model of prostate cancer [10, 17].
Similar to their studies, we found high specific tumor up-
take and higher kidney uptake when we injected different
doses of the bispecific antibody TF2 and the 111In-labeled
diHSG hapten-peptide RDC018. High renal uptake of
111In-RDC018 as a result of renal clearance might impair
imaging and image guidance in the vicinity of the kidneys
and bladder. This would, however, not reduce its potential
in colorectal cancer, since renal involvement or dissemin-
ation is rare [22]. On the contrary, renal clearance may be
advantageous for tracers targeting colorectal cancer. For
example, the dual-labeled humanized antibody hMN-14 is
mainly cleared via the hepatobiliary route, which results in
a relatively high fluorescence and radionuclide signal in
the liver [7]. Therefore, intraoperative detection of liver
metastasis or peritoneal metastasis present on the visceral
peritoneum of the liver may remain particularly challen-
ging with direct targeting strategies using antibodies. Fig-
ure 1 indicates higher liver uptake for 111In-RDC018 than
111In-IMP-288. The tumor-to-liver ratio, however, is still
greater than 5. In addition, the more favorable pharmaco-
kinetics of smaller molecules involved in pretargeting may
result in higher tumor-to-background ratios at early time
points after injection and might render them more suit-
able for theranostic purposes compared to antibody-based
strategies [8].
Several challenges remain before successful clinical
translation of this type of pretargeting strategies, including
optimizing dosing and timing, for example, the protein
dose of the antibody, dose and activity of the hapten, time
interval between antibody and hapten administration, and
interval between hapten administration and imaging or
surgery. Despite these challenges, several clinical trials that
show the safety and feasibility of TF2 bsAb and hapten
pretargeting strategies have been concluded [13, 23]. Re-
cently, Liu published a more quantitative description of
the pretargeting concept which contributes to overcoming
the challenges of clinical translation [24]. For fluorescence
image-guided surgery, also, translation of the preclinical
setup to the clinical setup at the operating rooms might
be challenging.
For colorectal cancer patients, the cornerstone in sur-
gical treatment is complete and radical resection. A sur-
geon’s ability to distinguish benign from malignant
tissue can be hampered by adhesions and fibrous or scar
tissue, which may be present due to earlier intra-abdom-
inal procedures or disease. Reliable assessment of tumor
burden can therefore sometimes only be performed dur-
ing the surgical procedure [25]. Imaging techniques
might aid in improving patient selection and the sur-
geon’s ability to distinguish between benign and malig-
nant [3]. Recently, CEA-based NIRF image-guided
surgery was shown to be safe and feasible in a clinical
trial with pancreatic cancer patients [26]. The same
tracer was used in a trial in colorectal cancer patients
with recurrent disease or peritoneal metastasis [27].
These results indicate that CEA-targeted NIRF image-
guided surgery may aid the surgeon in clinical deci-
sion-making during surgery; however, the specificity
found in these trials was 62%. Fluorescence has a
Fig. 4 Near-infrared fluorescence images (b, c) and microSPECT/CT images (a, d) of a mouse with a CEA-expressing intraperitoneal LS174T tumor
(arrow) 2 h after administration of 111In-RDC018. Pre-resection, the tumor can be clearly localized using microSPECT/CT (a, white arrow) and near-
infrared fluorescence imaging (b, white arrow). Subsequently, after euthanization, the tumor was resected with fluorescence image guidance (c,
white arrow). Finally, a post-resection microSPECT/CT was acquired (d) confirming the complete resection of the tumor nodule. The radio signal
of the renal clearance of 111In-RDC018 can also be observed in a and d
Elekonawo et al. EJNMMI Research            (2019) 9:86 Page 6 of 8
limited penetration depth and the occurrence of false-
negative tumor lesions in the former trials was mainly
caused by overlying blood or tissue. Adding a radio-
tracer for targeted multimodality imaging can serve a
multipurpose goal [14, 28]. It can serve as a preopera-
tive detection tool (e.g., SPECT or PET) of primary
tumor and/or (peritoneal) metastases [13]. Addition-
ally, intraoperative detection of lesions using a gamma
probe could be applied for deeper lesions and can po-
tentially increase specificity and sensitivity. Further-
more, intraoperative fluorescence imaging may
identify tumor lesions and might even be used as a
postoperative evaluation tool for complete removal.
Another advantage of adding a radiotracer to the
fluorescent targeting molecules is the ability to reli-
ably quantify the amount of tracer present in surgical
specimens. Standardization in quantification of fluores-
cent imaging is gaining more interest [29] and could bene-
fit from quantitative techniques using radiotracers.
Conclusions
Our findings elucidate a potential role of pretargeting
strategies in the search of optimum vehicles for image-
guided surgery and theranostic approaches in modern
treatment of colorectal cancer. In the current study, resec-
tion of pretargeted tumors with radio and fluorescence
guidance in a colorectal cancer model was shown to be
feasible. A limitation of our approach is the post mortem
dissection. Therefore, the next step is optimization of this
strategy before clinical translation in the future.
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